http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2265250-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58209a99602b20c360e8d2eb8b6bee97 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0007 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
filingDate | 2009-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4efbf710b9f1aa43e438f23f99cfe34e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02498bb0e3301fe69a354e17f8674aa7 |
publicationDate | 2010-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-2265250-A2 |
titleOfInvention | Enhanced transmucosal composition and dosage form |
abstract | The invention provides a transmucosal pharmaceutical composition comprising an active compound, a bile salt and an osmolality adjusting ingredient, wherein the osmolality adjusting ingredient generates a localized hyperosmotic environment and maintains an osmolality level for a period of time sufficient to produce hypertonicity- facilitated transmucosal transport of said active compound across the mucosal tissue. The invention also provides a solid transmucosal dosage form containing the composition, as well as a method of treatment comprising administering the same. In one embodiment, the active compound is a triptan compound, e.g., sumatriptan and zolmitriptan. |
priorityDate | 2008-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 195.